BF Biosciences Ltd
PPSX:BFBIO122.00
PKR
-2.50
(-2.01%)
ISIN
PK0148201012
Return %
Stock
S&P 500
1Y
-21.86
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Muhammad Farhan Rafiq
- Full Time Employees
- 852
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lahore Pakistan
- IPO Date
- Oct 21, 2024
- Website
- bfbio.com
- Similar Companies
- Business
- BF Biosciences Limited is a Pakistan-based biopharmaceutical company engaged in the research, development, manufacturing, licensing, and commercialization of biotechnology-derived pharmaceuticals, biosimilars, and specialized therapeutic formulations. Founded in 2006 as a pioneering joint venture between Ferozsons Laboratories Limited and Laboratorios Bagó S.A. of Argentina, the company operates as a subsidiary of Ferozsons Laboratories Limited and maintains its corporate headquarters and manufacturing operations in Lahore, Pakistan. The company develops and manufactures biopharmaceutical products across multiple therapeutic segments, offering products such as recombinant erythropoietin formulations for nephrology and chemotherapy-induced anemia; recombinant human interferon alpha and pegylated interferon formulations for the management of chronic hepatitis B and C; low molecular weight heparins, including enoxaparin sodium, and unfractionated heparins for cardiology, vascular surgery, and thromboprophylaxis; critical care antivirals, including remdesivir for severe viral infections; oncology biosimilars and cytotoxic injectables for cancer management; and specialized biological parenterals delivered in pre-filled syringes, liquid vials, and lyophilized ampoules. BF Biosciences distributes its portfolio to public healthcare institutions, tertiary hospitals, private clinics, and retail distribution channels across Pakistan, alongside active export operations to emerging markets across Central Asia, Southeast Asia, and Africa. In recent developments, the company completed its Initial Public Offering on the Pakistan Stock Exchange in October 2024 under the ticker BFBIO to fund a comprehensive brownfield expansion of its Raiwind manufacturing facility. This strategic expansion features the addition of advanced European pre-filled syringe lines, expanded freeze-drying and lyophilization capacities, and the introduction of new biosimilar and oncology product lines to meet increasing domestic demand and accelerate international market penetration.